NKF Innovation Fund Invests in Nephrogen to Advance One-Time Gene Editing Therapies for Kidney Disease
Investment supports advancement of a delivery platform built to solve the barrier that has kept genetic medicines out of the kidney, and a lead program in polycystic kidney disease. NEW YORK, Oct. 6, 2026 /PRNewswire/ -- The National Kidney Foundation (NKF) today announced an investment...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.